ISTITUTO PER LO STUDIO E LA PREVENZIONE E LA RETE ONCOLOGICA

Their core work

ISPRO is a Tuscan public health institute focused on cancer prevention, screening programs, and oncology network coordination. They specialize in population-based cancer screening (particularly breast cancer), epidemiological research, and translating genetic risk assessment into personalized prevention strategies. Their work bridges clinical oncology with public health policy, contributing real-world screening data and patient cohorts to European research consortia.

What they specialise in

How they've shifted over time

ISPRO's earlier H2020 involvement (2015) focused on environmental cancer risk factors through tobacco smoke exposure research. From 2018 onward, they shifted decisively toward precision oncology — personalized breast cancer screening using genetics and AI-based decision support for colorectal cancer treatment. The trajectory shows a clear move from general prevention research toward data-driven, personalized cancer medicine.

ISPRO is moving toward AI-assisted and genetics-based personalized cancer prevention, making them increasingly relevant for digital health and precision medicine consortia.

How they like to work

ISPRO participates as a contributing partner rather than leading consortia — they have never coordinated an H2020 project. They work in large consortia (64 unique partners across 14 countries), suggesting they contribute specialized screening data, patient cohorts, or regional clinical expertise to bigger European efforts. Their third-party role in REVERT indicates they can also provide targeted expertise without full consortium membership.

Connected to 64 unique partners across 14 countries, indicating broad European reach through large health consortia. Their network is built primarily through major multi-site clinical studies rather than repeated bilateral partnerships.

What sets them apart

ISPRO combines operational cancer screening infrastructure (running Tuscany's regional screening programs) with research capacity — a rare combination that provides both real patient data and implementation know-how. For consortium builders, they offer access to Italian population-level screening cohorts and practical experience translating research findings into public health policy. Their dual role as both a screening service provider and research participant makes them valuable for projects needing real-world validation.

Highlights from their portfolio

• MyPeBS
  Major international randomized trial (2018-2027) comparing personalized risk-stratified breast cancer screening to standard approaches — one of the largest precision prevention studies in Europe.
• TackSHS
  Addressed the emerging public health question of e-cigarette emissions alongside traditional secondhand smoke, combining exposure assessment with intervention design.